Answers are grounded in this paper and cite their sources.
INTRODUCTION Accurate Alzheimer’s disease (AD) detection remains challenging and often requires invasive or costly procedures. Blood-based metabolomic signatures offer a promising non-invasive approach. This study aimed to identify a serum metabolite panel and evaluate its performance alone and in combination with apolipoprotein E ( APOE ) ε4 genotype status for distinguishing AD from cognitively normal (CN) individuals. METHODS Baseline data from 594 participants in the Alzheimer’s Disease Neuroimaging Initiative (237 AD, 357 CN) were analyzed. High-resolution serum metabolomics (Biocrates MxP® Quant 500) and APOE genotype data were used for LASSO-based feature selection, followed by machine learning model training and evaluation on a held-out test set. RESULTS A panel of 151 metabolites distinguished AD from CN with high accuracy (test-set AUC=0.90). Adding APOE to the panel further improved model performance (AUC=0.91 versus AUC=0.75 for APOE alone; p <0.001), achieving strong sensitivity (0.92), specificity (0.84), and negative predictive value (0.94). Key predictive metabolites included bile acids, ether-linked phosphatidylcholines, and acylcarnitines, which are associated with pathways related to lipid metabolism, mitochondrial function, and the gut–liver–brain axis. CONCLUSION Integrating serum metabolomics with APOE enables accurate, non-invasive AD detection and offers a scalable screening approach with strong potential to rule out AD in primary care. ClinicalTrials.gov Identifier NCT00106899 and related ADNI phases.
No takes yet. Share an insight, caveat, or question.
Mukesha et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: